Agomab reports positive interim data in Crohn's disease trial - The Pharma Letter
This is an early positive interim report of a new oral drug (ALK5 inhibitor) aimed at fibrostenosing Crohn’s disease. Treatments that target intestinal strictures are an important area of research for people with...